CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

Ciprofloxacin and Dexamethasone

ciprofloxacin and dexamethasone· ingredient ciprofloxacinAntiinfectives· CIPROFLOXACIN HYDROCHLORIDE 3 mg/mL; DEXAMETHASONE 1 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$7.40
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per ML — the trend nobody else shows. 7 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other ciprofloxacin products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.

ProductNADAC / MLvs this
Cipro$0.11799−$7.28
Ciprofloxacin$0.11799−$7.28
Ciprofloxacin HCl Ophthalmic$1.62−$5.78
Ciprofloxacin Otic$6.85−$0.54750
CIPRO HC$34.87+$27.47
CILOXAN$74.28+$66.88

Medicare Part D coverage · CY2026

On 277 plan formularies · typical tier 4
Prior auth 0% · Step therapy 0% · Quantity limit 43% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.